Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pazopanib + capecitabine
- Development stage
- Unknown
- Lead developer
- Cure HHT
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of pazopanib, a multi-tyrosine kinase inhibitor that targets angiogenesis, and capecitabine, an oral fluoropyrimidine chemotherapy agent. This combination is being investigated for its potential efficacy in various cancer types, including metastatic breast cancer and advanced gastric cancer.
- Brand names
- VotrientXeloda
- Other names
- PazoXpazopanib plus capecitabine
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)CSF1R (Macrophage colony-stimulating factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on pazopanib + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pazopanib + capecitabine.